You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 699 Phase 2 trial of brentuximab vedotin (BV) with pembrolizumab (pembro) in patients with metastatic non-small cell lung cancer or metastatic cutaneous melanoma after progression on anti-PD-1 therapy

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
699 Phase 2 trial of brentuximab vedotin (BV) with pembrolizumab (pembro) in patients with metastatic non-small cell lung cancer or metastatic cutaneous melanoma after progression on anti-PD-1 therapy

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023302022
Dec 20237008
Jan 202495010
Feb 2024120010
Mar 2024124013
Apr 2024130014
May 2024178012
Jun 202413808
Jul 202412407
Aug 20248404
Sep 20246802
Oct 20248409
Nov 202411209
Dec 2024155014
Jan 2025144012
Feb 20251606
Mar 2025002
Apr 2025009
May 2025002
Jun 2025002
Total19440175